“I am really looking forward to seeing everyone at CX 2023 and it is going to be a great meeting. It is a pleasure and a privilege for us to be part of it and have the opportunity to present our trial data for the first time.”
Data and discussion on revascularisation treatment strategies for patients with chronic limb-threatening ischaemia (CLTI) will take centre stage at the CX 2023 Consensus update, with first results from the BASIL-2 (Bypass versus angioplasty in severe ischaemia of the leg-2) randomised controlled trial to be presented for the first time.
This is sure to be a monumental first-to-podium update and will be followed, as always, by discussion and audience participation. Attendees in London and remote participants will have the opportunity to pose questions to the BASIL-2 investigators, who—along with an expert panel—will interrogate the evidence in a roundtable discussion to reach consensus on this hotly debated topic.
Background:
This trial follows on from the first BASIL trial which was first published in The Lancet in 2005. The BASIL-1 trial found that, in patients presenting with severe limb ischaemia due to infrainguinal disease and who are suitable for surgery and angioplasty, a bypass-surgery first and a balloon-angioplasty-first strategy are associated with “broadly similar outcomes in terms of amputation-free survival,” and in the short term, “surgery is more expensive than angioplasty”.
BASIL-2 @ CX 2023:
During the session, BASIL-2 chief investigator Andrew Bradbury (Birmingham, UK) will deliver the first results from the trial. The upcoming session on revascularisation strategies in CLTI will also see participation from the USA, with BEST-CLI investigators Matthew Menard (Boston, USA) and Alik Farber (Boston, USA) providing a podium-first update on the trial and first-to podium quality-of-life data, respectively.
